Abstract
CDC25 dual specificity phosphatases activate the cyclin-dependent kinase complexes, allowing timely ordered progression through out the different phases of the eukaryotic cell cycle. In humans, there are three genes coding for the CDC25A, B and C proteins with both different and redundant specificities and regulations. The CDC25A member of this family acts during the G1 phase and at the G1/S transition by activating the CDK2/cyclin E and CDK2/cyclin A complexes, a function apparently not shared by the other members. In consequence, CDC25A is submitted to extra-cellular signals-dependent regulations involving in particular mitogenic signal transducers, and leading to modifications of its stability, its localization or its activity. In addition, CDC25A is up-regulated in various cancers, and the molecular mechanisms leading to this up-regulation are far from being understood. In this review, we will synthesize the current knowledge about CDC25A molecular regulations, and try to integrate these data in the cell proliferation and apoptotic functions described for the protein.
Keywords: CDC25A phosphatase, cell cycle, proliferation, apoptosis, G1/S transition, oncogenesis
Anti-Cancer Agents in Medicinal Chemistry
Title: CDC25A: A Rebel Within the CDC25 Phosphatases Family?
Volume: 8 Issue: 8
Author(s): Anne Fernandez-Vidal, Anne Mazars and Stephane Manenti
Affiliation:
Keywords: CDC25A phosphatase, cell cycle, proliferation, apoptosis, G1/S transition, oncogenesis
Abstract: CDC25 dual specificity phosphatases activate the cyclin-dependent kinase complexes, allowing timely ordered progression through out the different phases of the eukaryotic cell cycle. In humans, there are three genes coding for the CDC25A, B and C proteins with both different and redundant specificities and regulations. The CDC25A member of this family acts during the G1 phase and at the G1/S transition by activating the CDK2/cyclin E and CDK2/cyclin A complexes, a function apparently not shared by the other members. In consequence, CDC25A is submitted to extra-cellular signals-dependent regulations involving in particular mitogenic signal transducers, and leading to modifications of its stability, its localization or its activity. In addition, CDC25A is up-regulated in various cancers, and the molecular mechanisms leading to this up-regulation are far from being understood. In this review, we will synthesize the current knowledge about CDC25A molecular regulations, and try to integrate these data in the cell proliferation and apoptotic functions described for the protein.
Export Options
About this article
Cite this article as:
Fernandez-Vidal Anne, Mazars Anne and Manenti Stephane, CDC25A: A Rebel Within the CDC25 Phosphatases Family?, Anti-Cancer Agents in Medicinal Chemistry 2008; 8 (8) . https://dx.doi.org/10.2174/187152008786847684
DOI https://dx.doi.org/10.2174/187152008786847684 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Brain Delivery of Chemotherapeutics in Brain Cancer
Anti-Cancer Agents in Medicinal Chemistry Meet Our Editorial Board Member
Current Radiopharmaceuticals Targeting Never-In-Mitosis-A Related Kinase 5 in Cancer: A Review
Current Medicinal Chemistry Autophagy Regulators as Potential Cancer Therapeutic agents: A Review
Current Topics in Medicinal Chemistry Pyruvate Kinase M2: Regulatory Circuits and Potential for Therapeutic Intervention
Current Pharmaceutical Design Emerging Roles for Modulation of microRNA Signatures in Cancer Chemoprevention
Current Cancer Drug Targets Targeting DNA Repair Proteins: A Promising Avenue for Cancer Gene Therapy
Current Gene Therapy Effects of Galbanic Acid on Proliferation, Migration, and Apoptosis of Glioblastoma Cells Through the PI3K/Akt/MTOR Signaling Pathway
Current Molecular Pharmacology Evaluation of Non-Coding RNAs as Potential Targets in Head and Neck Squamous Cell Carcinoma Cancer Stem Cells
Current Drug Targets Cyclization in Opioid Peptides
Current Drug Targets Antineoplastic Activity, Structural Modification, Synthesis and Structure-activity Relationship of Dammarane-type Ginsenosides: An Overview
Current Organic Chemistry Update on Pharmacologic Retinal Vascular Toxicity
Current Pharmaceutical Design Targeting Apoptotic Signaling Pathways in Human Lung Cancer
Current Cancer Drug Targets Understanding the Pharmaceutical Aspects of Dendrimers for the Delivery of Anticancer Drugs
Current Drug Targets E2F1-Mediated Apoptosis as a Target of Cancer Therapy
Current Molecular Pharmacology Ex Vivo Liver – Directed Gene Therapy for the Treatment of Metabolic Diseases: Advances in Hepatocyte Transplantation and Retroviral Vectors
Current Gene Therapy Telomerase Modulation in Therapeutic Approach
Current Pharmaceutical Design MicroRNA Therapeutics: The Emerging Anticancer Strategies
Recent Patents on Anti-Cancer Drug Discovery A Key Role for Connexin Hemichannels in Spreading Ischemic Brain Injury
Current Drug Targets The Metastatic Process: Methodological Advances and Pharmacological Challenges
Current Medicinal Chemistry